Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.60 |
| ▸ | PARP1 | P09874 | 11/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.44 |
| ▸ | PARP6 | Q2NL67 | 2/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.44 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5211935 | 0.99 | HRH3 (0.59) | HRH3PARP1HRH1PARP2PARP6 | |
| SCHEMBL5210318 | 0.90 | HRH3 (0.59) | HRH3PARP1 | |
| SCHEMBL5213489 | 0.89 | HRH3 (0.57) | HRH3PARP1PARP2PARP6PARP3 | |
| SCHEMBL5209152 | 0.88 | HRH3 (0.56) | HRH3PARP1 | |
| SCHEMBL4032017 | 0.88 | HRH3 (0.53) | HRH3PARP1HRH1PARP2PARP6 | |
| SCHEMBL5210105 | 0.88 | HRH3 (0.60) | HRH3HRH1 | |
| SCHEMBL5211332 | 0.87 | HRH3 (0.56) | HRH3PARP1 | |
| SCHEMBL5210726 | 0.87 | HRH3 (0.55) | HRH3PARP1PARP2PARP6PARP3 | |
| SCHEMBL5212817 | 0.86 | HRH3 (0.61) | HRH3 | |
| SCHEMBL26015635 | 0.86 | HRH3 (0.53) | HRH3PARP1HRH1PARP2PARP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | claimed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | claimed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
| EP-1646620-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | HRH3 1/4885PARP1 1880/4885HRH1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.